https://www.selleckchem.com/sc....reening/natural-prod
After a median follow-up of 10.6 months, 25.7% of patients (123/479) had treatment failure. A theoretical different clinical decision based on the corrected drug concentrations was not associated with treatment failure (adjusted hazard ratio (HR) 1.452; 95% confidence interval (CI) 0.805-2.618; p = 0.216), which was consistent for both infliximab (adjusted HR 1.977; 95% CI 0.695-5.627; p = 0.201) and adalimumab (adjusted HR 1.484; 95% CI 0.721-3.054; p = 0.284). The drift in infliximab and adalimumab concentrations in t
Like
Comment
Share
